ACH
CHRS icon

ArrowMark Colorado Holdings’s Coherus Oncology CHRS Stock Holding History

ArrowMark Colorado Holdings’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,330
Closed -$62K – 327
2016
Q3 		$62K Buy
+2,330
New +$63.6K ﹤0.01% 293

Other funds holding CHRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ArrowMark Colorado Holdings's CHRS Position: Q4 2016 in Review

ArrowMark Colorado Holdings sold out of Coherus Oncology (CHRS) in Q4 2016, closing a stake of 2,330 shares — an estimated $62K sold.

ArrowMark Colorado Holdings first reported a position in CHRS in Q3 2016 and held it in 1 quarter. The position peaked at $62K in Q3 2016. 122 funds tracked by Wall St. Rank hold CHRS as of Q4 2016.

  • ArrowMark Colorado Holdings reported no remaining Coherus Oncology position as of Q4 2016 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 2,330 Coherus Oncology shares in Q4 2016, an estimated $62K.
  • ArrowMark Colorado Holdings first reported a position in Coherus Oncology in Q3 2016 and held it in 1 quarter.
  • ArrowMark Colorado Holdings's Coherus Oncology position peaked at $62K in Q3 2016.
  • 122 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2016.

Based on ArrowMark Colorado Holdings's 13F filing for Q4 2016, filed 14 Feb 2017.